» Articles » PMID: 9221772

Differential Autoreceptor Control of Somatodendritic and Axon Terminal Dopamine Release in Substantia Nigra, Ventral Tegmental Area, and Striatum

Overview
Journal J Neurosci
Specialty Neurology
Date 1997 Aug 1
PMID 9221772
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Dopamine (DA) is released from somatodendritic sites of neurons in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA), where it has neuromodulatory effects. The aim of this study was to evaluate the role of D2 autoreceptor inhibition in the regulation of this somatodendritic release in each region. Fast cyclic voltammetry at carbon fiber microelectrodes was used to measure electrically evoked DA release in vitro. Furthermore, we compared D2 regulation of somatodendritic release with the more familiar axon terminal release in caudate putamen (CPu) and nucleus accumbens (NAc). Evoked DA release was TTX-sensitive at all sites. There was significant D2 autoinhibition of DA release in SNc; however, this mechanism was two- to threefold less powerful, as compared with axon terminal release in CPu. In contrast to SNc, somatodendritic release in VTA was not under significant D2 receptor control, whereas release in the respective axon terminal region (NAc) was controlled strongly by autoinhibition. Thus, these data indicate that, first, autoinhibition via D2 receptors consistently plays a less significant role in the control of somatodendritic than axon terminal DA release, and, second, even at the level of somatodendrites themselves, D2 autoinhibition displays marked regional variation. In the light of previous data indicating that DA uptake processes are also less active in somatodendritic than in terminal regions, these results are interpreted as indicating that DA transmission is regulated differently in somatodendritic zones, as compared with axon terminals, and thus may have different functional consequences.

Citing Articles

The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models.

MacDonald H, Kleppe R, Szigetvari P, Haavik J Front Psychiatry. 2024; 15:1492126.

PMID: 39619336 PMC: 11604610. DOI: 10.3389/fpsyt.2024.1492126.


Dopamine release plateau and outcome signals in dorsal striatum contrast with classic reinforcement learning formulations.

Kim M, Gibson D, Hu D, Yoshida T, Hueske E, Matsushima A Nat Commun. 2024; 15(1):8856.

PMID: 39402067 PMC: 11473536. DOI: 10.1038/s41467-024-53176-7.


GABA co-released from striatal dopamine axons dampens phasic dopamine release through autoregulatory GABA receptors.

Patel J, Sherpa A, Melani R, Witkovsky P, Wiseman M, ONeill B Cell Rep. 2024; 43(3):113834.

PMID: 38431842 PMC: 11089423. DOI: 10.1016/j.celrep.2024.113834.


Dopamine Signaling in Substantia Nigra and Its Impact on Locomotor Function-Not a New Concept, but Neglected Reality.

Salvatore M Int J Mol Sci. 2024; 25(2).

PMID: 38256204 PMC: 10815979. DOI: 10.3390/ijms25021131.


Behavioral encoding across timescales by region-specific dopamine dynamics.

Jorgensen S, Ejdrup A, Lycas M, Posselt L, Madsen K, Tian L Proc Natl Acad Sci U S A. 2023; 120(7):e2215230120.

PMID: 36749722 PMC: 9963838. DOI: 10.1073/pnas.2215230120.


References
1.
Heeringa M, Abercrombie E . Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J Neurochem. 1995; 65(1):192-200. DOI: 10.1046/j.1471-4159.1995.65010192.x. View

2.
Le Moine C, Bloch B . Rat striatal and mesencephalic neurons contain the long isoform of the D2 dopamine receptor mRNA. Brain Res Mol Brain Res. 1991; 10(4):283-9. DOI: 10.1016/0169-328x(91)90086-d. View

3.
Jones S, Mickelson G, Collins L, Kawagoe K, Wightman R . Interference by pH and Ca2+ ions during measurements of catecholamine release in slices of rat amygdala with fast-scan cyclic voltammetry. J Neurosci Methods. 1994; 52(1):1-10. DOI: 10.1016/0165-0270(94)90048-5. View

4.
Reubi J, Emson P, Jessell T, Iversen L . Effects of GABA, dopamine, and substance P on the release of newly synthesized 3H-5-hydroxytryptamine from rat substantia nigra in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1978; 304(3):271-5. DOI: 10.1007/BF00507968. View

5.
OConnor J, Kruk Z . Pharmacological characteristics of 5-hydroxytryptamine autoreceptors in rat brain slices incorporating the dorsal raphe or the suprachiasmatic nucleus. Br J Pharmacol. 1992; 106(3):524-32. PMC: 1907542. DOI: 10.1111/j.1476-5381.1992.tb14369.x. View